Quince Therapeutics Inc (NASDAQ: QNCX) is -47.03% lower on its value in year-to-date trading and has touched a low of $0.51 and a high of $2.45 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The QNCX stock was last observed hovering at around $1.00 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $0.99, the stock is -17.63% and -25.94% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.11 million and changing -0.95% at the moment leaves the stock -19.91% off its SMA200. QNCX registered -0.60% loss for a year compared to 6-month gain of 28.14%. The firm has a 50-day simple moving average (SMA 50) of $1.33742 and a 200-day simple moving average (SMA200) of $1.236745.
The stock witnessed a -27.17% loss in the last 1 month and extending the period to 3 months gives it a -42.41%, and is -1.93% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.56% over the week and 8.38% over the month.
Quince Therapeutics Inc (QNCX) has around 36 employees, a market worth around $43.67M and $0.00M in sales. Distance from 52-week low is 93.61% and -59.57% from its 52-week high. The company has generated returns on investments over the last 12 months (-126.68%).
The EPS is expected to grow by 39.24% this year, but quarterly earnings will post 0.00% year-over-year.
52.0 institutions hold shares in Quince Therapeutics Inc (QNCX), with institutional investors hold 27.26% of the company’s shares. The shares outstanding are 44.00M, and float is at 32.73M with Short Float at 4.69%. Institutions hold 23.57% of the Float.
Quince Therapeutics Inc (QNCX) Insider Activity
The most recent transaction is an insider purchase by Thye Dirk, the company’s CEO AND CHIEF MEDICAL OFFICER. SEC filings show that Thye Dirk bought 77,000 shares of the company’s common stock on Aug 30 ’24 at a price of $0.70 per share for a total of $53900.0. Following the purchase, the insider now owns 0.84 million shares.
Quince Therapeutics Inc disclosed in a document filed with the SEC on Aug 29 ’24 that Thye Dirk (CEO AND CHIEF MEDICAL OFFICER) bought a total of 77,500 shares of the company’s common stock. The trade occurred on Aug 29 ’24 and was made at $0.69 per share for $53475.0. Following the transaction, the insider now directly holds 0.77 million shares of the QNCX stock.
Still, SEC filings show that on Aug 20 ’24, Ryan Charles S. (PRESIDENT) acquired 48,387 shares at an average price of $0.65 for $31452.0. The insider now directly holds 122,461 shares of Quince Therapeutics Inc (QNCX).
